Cross Pharmaceutical Investigator Databank

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2012
  • Initiating Organization: Janssen
  • Initiator Type: Industry
  • No disease focus
  • Location: North America


The Cross Pharmaceutical Investigator Databank is a precompetitive collaboration established by Janssen, Merck, and Lilly and designed to make the clinical trial process more efficient. The goal is to improve efficiencies and reduce the administrative burden related to clinical research, making it easier for investigators to participate in clinical trials on an ongoing basis. The databank includes participating investigators in Europe, North America, Africa, Asia, and Central/South America focusing on a variety of therapeutic areas including cardiovascular, oncology, neurology, and endocrinology/diabetes.


The Investigator Databank serves as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed. This will allow participating pharmaceutical companies to reduce time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites.

The Investigator Databank benefits sponsors and investigators throughout a trial’s setup and execution process. It can provide insight and validation to protocol design feasibility, faster selection of investigators, faster site startup time, and improved ability to set realistic recruitment plans and achieve better risk modeling.

Through the precompetitive collaboration, participating companies recognize each other’s GCP training, reducing the need for redundant training of investigators. By pooling investigator lists, training records, and site qualifications, all participating companies have a much larger and more complete and accurate record of potential clinical trial sites, making it easier to identify appropriate sites for future clinical studies.

Consortium History

Nov. 5, 2012: The Investigator Databank was established.

Structure & Governance

The Investigator Databank is open to all pharmaceutical companies. Those interested in participating should contact Andreas Koester, Head of Clinical Trial Innovation at Janssen Healthcare Innovation (

Data Sharing

The Investigator Databank will include a record for each physician investigator who has opted to participate. This record will provide current data for the clinical trial site, including dates of most recently completed industry standard GCP training as well as an inventory of site infrastructure. The Investigator Databank will not include patient data. Only information about investigators who have opted in for inclusion in the Investigator Databank will be shared. The Investigator Databank will be hosted by, an independent, third-party company with expertise in clinical trial information technology and investigator community management.

For consenting investigators, the information will be shared among all participating pharmaceutical companies to identify potential sites for upcoming trials. The data are also used for reference purposes, to set recruitment targets and timelines, and to reference GCP training records of other sponsors to support waiving of GCP training requirements if possible. Participating companies will not share investigator information with one another unless he or she “opts in.”

Points of Contact

Andreas Koester
Head of Clinical Trial Innovation
Janssen Healthcare Innovation

Sponsors & Partners






Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.